Debra Montague - Founder & Chairman
I was previously a Marketing Manager with a pharmaceutical company and worked for them for over 20 years. I have a 21 year old son and 2 dogs and I am sometimes confused which is better house trained!
I was diagnosed with ALK+ LC in October 2016, which was a great shock as my only symptom was a cough and I had never smoked.
Since diagnosis, I have walked a marathon, did the longest and fastest zip wire in Europe, abseiled down Liverpool cathedral, completed a triathlon and jumped out of a plane at 15,000 feet.
I decided to set up a UK version of the world wide group as we have specific challenges in the UK that we need to focus on. I am looking forward to putting ALK+ UK on the map as a patient group that changes the face of lung cancer and ends the stigma.
Rebecca Stebbings - Communications Lead
I previously worked for the NHS and charity Age U.K. on various health improvement projects. At the very heart of these projects is always the objective to reduce health inequalities.
It was only when a loved one was diagnosed with ALK+ lung cancer in 2017, that I became all too aware of the huge disparity in outcomes for lung cancer patients versus many other cancers.
My aim is to help ALK+ UK raise awareness on a national level around the reasons for this disparity and challenge the stereotyping of lung cancer patients. I believe this will contribute significantly to reducing what is currently a tragic inequality in cancer patient outcomes.
Professor Susan Eastwood
I am Director of the Institute of Environment, Health and Societies and a Professor of Environmental Toxicology at Brunel Univerity. I am interested in how environmental contaminants affect the health of wildlife and humans as exposure to these is a part of our everyday lives, particularly in urban environments where 80% of UK citizens live.
I recently lost my dear friend Ruth Strauss to Alk Positive lung cancer. Ruth was diagnosed at stage 4 in December 2017 and died a year later. Being a trustee of this charity offers me a unique opportunity to help increase support for patients such as Ruth and to raise awareness and funds to make an impact on research. I am honoured to be a member of the Board.
Graham Lavender - Secretary and Treasurer
I am a retired Director of Environmental Health and Housing. I was also Chairman of a Council of Voluntary Service; Non-Executive Director of a NHS Trust; Lay Advocate for people with learning or mental health difficulties and Lay Assessor for Social Services.
Experienced in administration and financial management. Sound knowledge of charity law.
Angela Field - Fundraising Lead
I was diagnosed Alk+ lung cancer in April 2014 whilst still fit and active and regularly running marathons.
I have worked in IT/Telecoms for 20 years and I am experienced in Project and Process Management.
I am looking forward to being involved with the charity and I think that I can add value in the role of Fundraising Lead
I work in IT as a DevOps engineer and was diagnosed Alk+ lung cancer in April 2019 - a real surprise.
I am delighted to join the board of the Charity and hope to contribute to changing the perception of lung cancer. I am looking forward to helping and supporting fellow patients and to promoting the Charity so than many more ALK+ patients can benefit from the mutual support that we can offer.
Professor Sanjay Popat BSc, MBBS, FRCP, PhD
Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at The Royal Marsden and Honorary Clinical Senior Lecturer in the Molecular Genetics and Genomics Group at the National Heart and Lung Institute, Imperial College London.
He is Chair of the British Thoracic Oncology Group (BTOG), and also the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He is Cancer Divisional Co-Director of the NIHR-London South Clinical Research Network. He is active in the European Organisation for Research and Treatment of Cancer (EORTC) Lung Group, the European Thoracic Oncology Platform (ETOP), and the International Thymic Malignancy Interest Group (ITMIG).
Fin McCaul - Fellow of the Pharmaceutical Society
Fin is Managing Director of Prestwich Pharmacy. His role at Greater Manchester LPC involves leading on contractor engagement. He has worked with a variety of public health groups and is currently the long-term conditions lead for NHS Bury CCG, working with GPs, other primary care providers and secondary care. Fin also speaks and delivers training at local and national events.
Sally Elms - Creative Planet
Creative Planet is an advertising and marketing agency that works in many different sectors and across all communication channels.
Sally is founder and Creative Director and is experienced in translating a thought or idea into a visual execution. She is able to understand an overall strategy and make a significant contribution to further enhancing that strategy before moving to implementation.
Kim Grant - IT
Kim has over 20 years experience in the IT industry, principally providing desktop and networking support.
She was diagnosed with ALK Positive lung cancer in May 2018 and eight days after diagnosis had brain surgery to reduce a brain tumour. Kim is still working and is a single mum looking after two children.
She has completed a Wing Walk to raise funds for the Charity.
Holly Jackson - Social Media
I am currently studying a degree in Pharmacology with an interest in the biological and pharmacological side of cancer research and targeted drugs. I’ve always been actively involved in a variety of charity work, but it wasn’t until a colleague whose wife has been diagnosed with ALK+ Lung Cancer told me of this group, that I had any real understanding of Non-Small Cell Lung Cancers and the incredible inequality and stigma surrounding lung cancer.
Since starting my journey of discovery and education around NSCLC’s, I have been repeatedly shocked by the lack of awareness and funding for research into these types of cancer. I am very excited to become a part of this fantastic team to help spread awareness about ALK+ UK in both the general public and the medical experts of the future.